Patents Assigned to Pulmokine, Inc.
  • Combination therapy for treating pulmonary hypertension
    Patent number: 11364238
    Abstract: The present disclosure describes a method of treating pulmonary disorders, such as pulmonary arterial hypertension, using a combination of a PDGF receptor kinase inhibitor, PDEV inhibitor, and an endothelin receptor antagonist. The compounds can inhibit cell growth and proliferation and target the underlying pathology of PAH.
    Type: Grant
    Filed: September 20, 2019
    Date of Patent: June 21, 2022
    Assignee: PULMOKINE, INC.
    Inventor: Lawrence S. Zisman
  • Non-selective kinase inhibitors
    Patent number: 10532994
    Abstract: Disclosed herein are compounds, compositions, and methods for preventing and treating proliferative diseases associated with aberrant receptor tyrosine kinase (RTK) activity. The therapeutic indications described herein more specifically relate to the non-selective inhibition of RTKs associated with vascular and pulmonary disorders.
    Type: Grant
    Filed: February 12, 2019
    Date of Patent: January 14, 2020
    Assignees: PULMOKINE, INC., GILEAD SCIENCES, INC.
    Inventor: Lawrence S Zisman
  • Non-selective kinase inhibitors
    Patent number: 10246438
    Abstract: Disclosed herein are compounds, compositions, and methods for preventing and treating proliferative diseases associated with aberrant receptor tyrosine kinase (RTK) activity. The therapeutic indications described herein more specifically relate to the non-selective inhibition of RTKs associated with vascular and pulmonary disorders.
    Type: Grant
    Filed: July 26, 2017
    Date of Patent: April 2, 2019
    Assignee: PULMOKINE, INC
    Inventor: Lawrence S Zisman
  • Combination therapy for treating pulmonary hypertension
    Patent number: 10231966
    Abstract: The present disclosure describes a method of treating pulmonary disorders, such as pulmonary arterial hypertension, using a combination of a PDGF receptor kinase inhibitor, PDEV inhibitor, and an endothelin receptor antagonist. The compounds can inhibit cell growth and proliferation and target the underlying pathology of PAH.
    Type: Grant
    Filed: October 27, 2017
    Date of Patent: March 19, 2019
    Assignee: Pulmokine, Inc.
    Inventor: Lawrence S. Zisman
  • Spray-dry formulations
    Patent number: 9925184
    Abstract: Disclosed herein are compounds, compositions, and methods for preventing and treating proliferative diseases associated with aberrant receptor tyrosine kinase (RTK) activity. The therapeutic indications described herein more specifically relate to the non-selective inhibition of RTKs associated with vascular and pulmonary disorders.
    Type: Grant
    Filed: October 10, 2014
    Date of Patent: March 27, 2018
    Assignees: Pulmokine, Inc., Gilead Sciences, Inc.
    Inventor: Lawrence S Zisman
  • Non-selective kinase inhibitors
    Patent number: 9815815
    Abstract: Disclosed herein are compounds, compositions, and methods for preventing and treating proliferative diseases associated with aberrant receptor tyrosine kinase (RTK) activity. The therapeutic indications described herein more specifically relate to the non-selective inhibition of RTKs associated with vascular and pulmonary disorders.
    Type: Grant
    Filed: January 9, 2014
    Date of Patent: November 14, 2017
    Assignees: PULMOKINE, INC., GILEAD SCIENCES, INC.
    Inventor: Lawrence S Zisman
  • Therapeutic Indications of Kinase Inhibitors
    Publication number: 20150352111
    Abstract: Disclosed herein are compounds, compositions, and methods for preventing and treating diseases associated with protein kinase activity. The therapeutic indications described herein relate to receptor tyrosine kinase (RTK) inhibition for the treatment or prevention of vascular conditions and proliferative disorders. The disclosure also relates to irreversible RTK inhibitors.
    Type: Application
    Filed: January 9, 2014
    Publication date: December 10, 2015
    Applicant: Pulmokine, Inc.
    Inventor: Lawrence S. ZISMAN
  • NON-SELECTIVE KINASE INHIBITORS
    Publication number: 20150353527
    Abstract: Disclosed herein are compounds, compositions, and methods for preventing and treating proliferative diseases associated with aberrant receptor tyrosine kinase (RTK) activity. The therapeutic indications described herein more specifically relate to the non-selective inhibition of RTKs associated with vascular and pulmonary disorders.
    Type: Application
    Filed: January 9, 2014
    Publication date: December 10, 2015
    Applicant: PULMOKINE, INC.
    Inventor: Lawrence ZIAMAN